For most patients with chronic kidney disease (CKD), the risk of experiencing a cardiovascular related death is greater than the risk of progressing to end-stage renal disease (ESRD). Read more ...
BTG plc (LSE:BGC), the life sciences company, announces that the full results of the US phase II safety study of Varisolve® are being presented today at the American College of Phlebology (ACP) 22nd Annual Congress. The results confirm that treatment with Varisolve® in subjects with right-to-left (R-L) cardiac shunts, which may allow residual bubbles following treatment to enter the cerebral arterial circulation, does not cause cerebral injury. Read more ...
Vermed, a manufacturer of quality cardiac monitoring and diagnostic electrodes, introduces a new line of Defibrillation Pads with features new and unique to the market. Vermed pads use a new Universal Connector System (UCS) that allows standardization of the defib pads throughout any facility. This is a tremendous step toward patient safety and industry compliance. Read more ...
"Because of the scarcity of available organs, the Montefiore-Einstein Heart Center is looking at new ways for heart disease patients to go on living with their own hearts. This is a paradigm shift in the way we approach the failing heart," says Daniel Goldstein, MD, Surgical Director of the heart Transplant and Mechanical Assist Device Program. On Thursday, November 13th at 7:00pm on Read more ...
The combination of health risks known as metabolic syndrome affects slightly less than a quarter of the U.S. workforce and is linked to increased absenteeism and poorer health status, reports a study in the October Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM). Read more ...
A database launched today will help identify the incidence and causes of sudden cardiac death and save the lives of people who may currently be at risk from the inherited heart condition that can strike without warning, the Department of Health announced today. Read more ...
Boston Scientific Corporation (NYSE: BSX) today announced that the first patient was enrolled in the SEPTAL CRT clinical study, sponsored by the Company's Cardiac Rhythm Management (CRM) group. The patient was enrolled in France by Prof. Christophe Leclercq MD from CHU-Hôpital Pontchaillou, Rennes. Read more ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment